Doheny Asset Management CA held its position in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) during the first quarter, according to its most recent disclosure with the SEC. The fund owned 6,150 shares of the biotechnology company’s stock at the end of the first quarter. Doheny Asset Management CA’s holdings in Five Prime Therapeutics were worth $222,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of FPRX. ARK Investment Management LLC purchased a new position in shares of Five Prime Therapeutics during the fourth quarter worth $160,000. Suntrust Banks Inc. purchased a new position in shares of Five Prime Therapeutics during the third quarter worth $219,000. Creative Planning raised its position in shares of Five Prime Therapeutics by 42.6% in the first quarter. Creative Planning now owns 6,690 shares of the biotechnology company’s stock worth $242,000 after buying an additional 2,000 shares during the last quarter. Arxis Securities LLC purchased a new position in shares of Five Prime Therapeutics during the first quarter worth $267,000. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Five Prime Therapeutics during the first quarter worth $375,000. Hedge funds and other institutional investors own 93.38% of the company’s stock.
Shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) traded down 1.15% during mid-day trading on Friday, reaching $29.34. 191,361 shares of the company’s stock traded hands. The stock’s market capitalization is $818.50 million. Five Prime Therapeutics Inc has a 12-month low of $28.51 and a 12-month high of $60.98. The company’s 50-day moving average price is $32.38 and its 200-day moving average price is $44.16.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.25. Five Prime Therapeutics had a return on equity of 59.23% and a net margin of 64.94%. The company had revenue of $10.13 million during the quarter, compared to analyst estimates of $6.05 million. During the same quarter in the prior year, the company posted ($0.49) earnings per share. The business’s revenue was up 55.8% compared to the same quarter last year. Analysts anticipate that Five Prime Therapeutics Inc will post ($4.60) earnings per share for the current year.
WARNING: “Five Prime Therapeutics Inc (FPRX) Stake Maintained by Doheny Asset Management CA” was originally published by Mideast Time and is the property of of Mideast Time. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.mideasttime.com/five-prime-therapeutics-inc-fprx-stake-maintained-by-doheny-asset-management-ca/1708922.html.
A number of brokerages recently commented on FPRX. Jefferies Group LLC reaffirmed a “buy” rating and issued a $55.00 price target on shares of Five Prime Therapeutics in a report on Monday. Instinet began coverage on shares of Five Prime Therapeutics in a report on Wednesday, March 1st. They issued a “buy” rating and a $94.00 price target for the company. Nomura began coverage on shares of Five Prime Therapeutics in a report on Wednesday, March 1st. They issued a “buy” rating for the company. Zacks Investment Research raised shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a report on Wednesday, April 26th. Finally, TheStreet downgraded shares of Five Prime Therapeutics from a “c” rating to a “d+” rating in a report on Monday, March 20th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $59.00.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).
Receive News & Ratings for Five Prime Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.